ReviewNature reviews. Microbiology2020
Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies.
Review in Nature reviews. Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482553 (Evaluation of the Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli Isolated From Assiut University Hospitals), which is not on this map. Cited by 265 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli Isolated From Assiut University Hospitals
Who cites it
265 citing papers in PubMed, 4 syntheses or guidelines pooled it, 521 citations in OpenAlex.
- Antimicrobial Efficacy of Endogenous Blue Light Photoinactivation (400-470 nm) AgainstMedical sciences (Basel, Switzerland) · 2026Pooled it
- Carbapenem-resistant Enterobacteriaceae in the livestock, humans and environmental samples around the globe: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Urinary tract infections and risk of preterm birth: a systematic review and meta-analysis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Pooled it
- Recurrent Urinary tract infections and type 2 diabetes mellitus: a systematic review predominantly in women.Frontiers in urology · 2023Pooled it
- Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy.Materials today. Bio · 2026Review
- Article
- Urinary Tract Infections: Molecular Determinants of Uropathogenicity and Their Translation into Contemporary Clinical Practice.International journal of molecular sciences · 2026Review
- Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli.Nature communications · 2026Article
- Comparative efficacy of oral antibiotics against intracellular populations of uropathogenic Escherichia coli and bladder cell inflammatory response.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The Synergy Between a Silver-Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage.Molecular microbiology · 2026Article
- Machine learning models for early detection of urinary tract infections in kidney transplant patients.International urology and nephrology · 2026Article
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Genetic control of Group 3 (K96) capsule synthesis and complement resistance in extraintestinal pathogenicmSphere · 2026Article
- Significant variability in virulence factors and antibiotic resistance of uropathogenic Escherichia coli strains may be counteracted by their susceptibility to lytic bacteriophages.Scientific reports · 2026Article
- Fosfomycin susceptibility and molecular detection of fosA-mediated resistance among gram-negative uropathogens from a tertiary care hospital in Lucknow, India.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Rapid diagnostics innovations for urinary tract infections using molecular biology, artificial intelligence and antimicrobial resistance surveillance: a comprehensive review.Molecular biology reports · 2026Review
- Essential role for the urothelial plaque in Gram-negative urinary tract infections.Scientific reports · 2026Article
- Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.Folia microbiologica · 2026Review
- From adhesion to gene regulation: tea tree essential oil suppresses Uropathogenic Escherichia coli colonization while triggering csgA-mediated biofilm stress paradox.Molecular biology reports · 2026Article
- Uropathogenic profiles and antibiotic resistance in gynecological cases: a microbial surveillance study from Northeast India.Scientific reports · 2026Article
205 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Urinary tract infections (UTIs) are common, recurrent infections that can be mild to life-threatening. The continued emergence of antibiotic resistance, together with our increasing understanding of the detrimental effects conferred by broad-spectrum antibiotic use on the health of the beneficial microbiota of the host, has underscored the weaknesses in our current treatment paradigm for UTIs. In this Review, we discuss how recent microbiological, structural, genetic and immunological studies have expanded our understanding of host-pathogen interactions during UTI pathogenesis. These basic scientific findings have the potential to shift the strategy for UTI treatment away from broad-spectrum antibiotics targeting conserved aspects of bacterial replication towards pathogen-specific antibiotic-sparing therapeutics that target core determinants of bacterial virulence at the host-pathogen interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.